两种妊娠期糖尿病筛查策略的围产期结局:一项随机对照试验
本研究为单中心、盲法、随机对照实效性试验,比较IADPSG与Carpenter-Coustan两种妊娠期糖尿病筛查策略对围产期结局的影响。共921名孕妇随机分组,IADPSG组GDM诊断率和药物治疗率更高,但两组大于胎龄儿发生率无差异,IADPSG组新生儿发病率更高但研究相关不良事件更少。
要点
- IADPSG组GDM诊断率14.4%,显著高于Carpenter-Coustan组的4.5%。
- 两组大于胎龄儿发生率无显著差异,风险降低0.90(97.5%CI 0.53-1.52)。
- IADPSG组新生儿发病率更高,但研究相关不良事件更少。
核心结论
- IADPSG筛查标准较Carpenter-Coustan诊断并治疗更多妊娠期糖尿病孕妇,但未降低大于胎龄儿、孕产妇或新生儿发病率。
研究设计与样本
- 单中心、盲法、随机对照实效性试验,2015年6月至2019年2月入组1016名参与者,921名随机分配至IADPSG组(n=461)或Carpenter-Coustan组(n=460)。
主要发现
- IADPSG组GDM发生率14.4%,Carpenter-Coustan组4.5%(P<.001)。
- IADPSG组糖尿病药物使用率9.3%,Carpenter-Coustan组2.4%(P<.001)。
- 大于胎龄儿总体风险降低0.90(97.5%CI 0.53-1.52),非GDM孕妇中风险降低0.85(97.5%CI 0.49-1.48)。
- IADPSG组新生儿发病率更高,但研究相关不良事件更少。
- 小于胎龄儿、剖宫产和孕产妇发病率复合结局两组无显著差异。
关键数值与推荐
- 采用非空腹50g口服葡萄糖耐量试验,若血糖<200 mg/dL(<11.1 mmol/L)则随机进入进一步筛查。
- 主要结局为大于胎龄儿发生率,预设次要结局包括小于胎龄儿、剖宫产及新生儿和孕产妇不良围产期结局复合指标。
临床怎么用
- IADPSG标准增加GDM诊断和治疗,但未改善大于胎龄儿或母婴发病率,临床选择筛查策略需权衡诊断增加与结局获益。
局限性
- 单中心研究可能限制外推性;样本量基于预期15%的大于胎龄儿发生率和7%绝对风险降低计算。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate differences in short-term perinatal outcomes between the two prominent screening strategies for gestational diabetes mellitus, the International Association of Diabetes and Pregnancy Study Groups (IADPSG) and Carpenter-Coustan. METHODS: In this single-site, blinded, randomized, comparative effectiveness trial, participants received a nonfasting 50-g oral glucose tolerance test and, if less than 200 mg/dL (less than 11.1 mmol/L), were randomized to further screening with either IADPSG or Carpenter-Coustan criteria. Gestational diabetes treatment occurred per routine clinical care. The primary outcome was incidence of large-for-gestational-age (LGA) neonates. Prespecified secondary outcomes included small-for-gestational-age (SGA) neonates, cesarean birth, and neonatal and maternal composites of adverse perinatal outcomes. Assuming a 15% incidence of LGA neonates in the Carpenter-Coustan group, 782 participants provided more than 80% power to detect a 7% absolute risk reduction with the use of IADPSG; planned recruitment was 920 for anticipated attrition. RESULTS: From June 2015 to February 2019, 1,016 participants were enrolled and 921 were randomized to IADPSG (n=461) or Carpenter-Coustan (n=460) groups. Gestational diabetes incidence (14.4% vs 4.5%, P<.001) and diabetes medication use (9.3% vs 2.4%; P<.001) were more common in the IADPSG group; there were no differences in LGA neonates, either overall (risk reduction 0.90, 97.5% CI 0.53-1.52) or among women without gestational diabetes (risk reduction 0.85, 97.5% CI 0.49-1.48). Those screened with IADPSG had higher rates of neonatal morbidity but fewer study-related adverse events. Rates of SGA neonates, cesarean birth, and maternal morbidity composite did not differ significantly between study groups. CONCLUSIONS: The IADPSG screening criteria resulted in more women diagnosed and treated for gestational diabetes than Carpenter-Coustan without reducing the incidence of LGA birth weight or maternal or neonatal morbidity. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02309138.
引用
- Davis EM, Abebe KZ, Simhan HN, et al. Perinatal Outcomes of Two Screening Strategies for Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstet Gynecol. 2021. PMID: 34259458. doi:10.1097/AOG.0000000000004431
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。